These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8461397)

  • 21. The role of IA in G-cell activation.
    Swain SL; Dutton RW
    Transplant Proc; 1981 Dec; 13(4):1843-5. PubMed ID: 6977219
    [No Abstract]   [Full Text] [Related]  

  • 22. The use of class II MHC binding peptides in immunotherapy.
    Wraith DC
    Br J Rheumatol; 1991; 30 Suppl 2():14-6. PubMed ID: 1993249
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-class II antibody treatment in autoimmune diseases.
    Boitard C
    Immunol Ser; 1993; 59():279-93. PubMed ID: 8461393
    [No Abstract]   [Full Text] [Related]  

  • 24. Induction of Ia-like antigens by a group A streptococcal product with mitogenic activity.
    Quagliata F; Beckerdite-Quagliata S; Russo C; Bisno A; Indiveri F; Pellegrino M; Ferrone S
    Transplant Proc; 1981 Mar; 13(1 Pt 2):1049-50. PubMed ID: 7022915
    [No Abstract]   [Full Text] [Related]  

  • 25. Peptide partners call the tune.
    Lanzavecchia A; Watts C
    Nature; 1994 Sep; 371(6494):198-9. PubMed ID: 8078577
    [No Abstract]   [Full Text] [Related]  

  • 26. Characterization of three new intra-I region recombinant mouse strains, B10.ASR7 (H-2as3), B10.BAR4 (H-2h6), and B10.BASR1 (H-2as4).
    Allen PM; Gutmann DH; Sher MR; Niederhuber JE
    Immunogenetics; 1984; 19(2):175-8. PubMed ID: 6421725
    [No Abstract]   [Full Text] [Related]  

  • 27. Liposome-mediated peptide loading of MHC-DR molecules in vivo.
    t Hart BA; Elferink DG; Drijfhout JW; Storm G; van Blooijs L; Bontrop RE; de Vries RR
    FEBS Lett; 1997 Jun; 409(1):91-5. PubMed ID: 9199510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approaches to therapy of autoimmune disease.
    Steinman L; Trotter J; Waldor M; Sriram S
    Concepts Immunopathol; 1985; 1():85-95. PubMed ID: 3879936
    [No Abstract]   [Full Text] [Related]  

  • 29. [Suppression of primary immune reaction through L-asparaginase].
    Pappas A; Scheurlen PG
    Verh Dtsch Ges Inn Med; 1971; 77():1165-8. PubMed ID: 4949691
    [No Abstract]   [Full Text] [Related]  

  • 30. Alternative pathways of T-cell activation and positive clonal selection.
    Patarca R; Singh RP; Wei FY; Iregui MV; Singh P; Schwartz J; Cantor H
    Immunol Rev; 1990 Aug; 116():85-100. PubMed ID: 1977691
    [No Abstract]   [Full Text] [Related]  

  • 31. Regulatory T cells in pregnancy. V. Allopregnancy-induced T-cell-suppressor factor is H-2 restricted and bears Ia determinants.
    Chaouat G; Voisin GA
    Cell Immunol; 1981 Jul; 62(1):186-95. PubMed ID: 6973408
    [No Abstract]   [Full Text] [Related]  

  • 32. The autologous mixed lymphocyte reaction. A precautionary note.
    Hellmann D; Stobo J
    Arthritis Rheum; 1982 Feb; 25(2):121-5. PubMed ID: 7039628
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunodominance in T lymphocyte recognition.
    Berzofsky JA
    Immunol Lett; 1988 Jun; 18(2):83-92. PubMed ID: 3042616
    [No Abstract]   [Full Text] [Related]  

  • 34. Expanding the peptidome for immunotherapy.
    Neefjes J
    Blood; 2015 Sep; 126(10):1154-6. PubMed ID: 26337350
    [No Abstract]   [Full Text] [Related]  

  • 35. Approaches toward peptide-based immunotherapy of autoimmune diseases.
    Adorini L; Guéry JC; Trembleau S
    Springer Semin Immunopathol; 1992; 14(2):187-99. PubMed ID: 1475744
    [No Abstract]   [Full Text] [Related]  

  • 36. Ir gene control of mouse responses to poly(GluArgAla) and poly(ArgAla).
    Grun JL; Maurer PH
    Immunogenetics; 1988; 28(1):61-3. PubMed ID: 3132423
    [No Abstract]   [Full Text] [Related]  

  • 37. Quieting T cells with Slfn2.
    Horton MR; Powell JD
    Nat Immunol; 2010 Apr; 11(4):281-2. PubMed ID: 20300134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uveitogenic epitopes of retinal S-antigen are generated in vivo via an alternative antigen-presentation pathway.
    Liversidge J; Dawson R; Dick AD; Forrester JV
    Immunology; 1998 Jun; 94(2):271-8. PubMed ID: 9741352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of T-cell activation by administration of MHC class II-binding peptides.
    Adorini L; Guéry JC
    Immunol Ser; 1993; 59():331-43. PubMed ID: 8461397
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-V beta TcR monoclonal antibodies identify and can activate anergic T cells from mice rendered neonatally tolerant of class II alloantigens.
    Levy RB; Jones M; Streilein JW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):360-1. PubMed ID: 8438335
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.